CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-23 | Scopa James Paul Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-06-23 | Nielsen Jack Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-06-23 | Nuechterlein Carole Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-06-23 | Martell Bridget A Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-02-04 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2022-02-04 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +26,250 | 26,250 | ||
| 2022-02-04 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +323,400 | 323,400 | ||
| 2022-02-04 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +80,850 | 80,850 | ||
| 2022-02-04 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2022-02-04 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +26,250 | 26,250 | ||
| 2022-02-04 | Quan Lucinda Y. See Remarks | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2022-02-04 | Quan Lucinda Y. See Remarks | Grant or award · Stock Option (Right to Buy) | +26,250 | 26,250 | ||
| 2022-02-04 | Beigelman Leonid President | Grant or award · Stock Option (Right to Buy) | +226,800 | 226,800 | ||
| 2022-02-04 | Beigelman Leonid President | Grant or award · Stock Option (Right to Buy) | +56,700 | 56,700 | ||
| 2021-11-16 | Martell Bridget A Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2021-06-17 | Nielsen Jack Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-06-17 | Woiwode Thomas Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-06-17 | Hirth Peter Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-06-17 | Nuechterlein Carole Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-06-11 | Woiwode Thomas Director | Other disposition | −485,979 | 1,457,937 |
Page 6 of 12 · 238 trades